Navigation Links
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America

Six Million Doses of Stamaril(TM) Vaccine Shipped in Record Time to Brazil

and Paraguay

LYON, France, February 26 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, announced today that six million doses of Stamaril(TM)(1) yellow fever vaccine have been shipped upon UNICEF's request to respond to the yellow fever epidemic in Latin America.

Brazil received four million doses of Stamaril(TM) vaccine early February and an additional two million doses were shipped to Paraguay over the weekend in response to urgent requests from Health Authorities.

"Sanofi Pasteur mobilized its teams to make this public health emergency a priority," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "This ability to respond to an emergency in record time illustrates the company's commitment to global health."

The yellow fever vaccine that was provided to Brazil and Paraguay is part of the UNICEF vaccine stockpile which is reserved for outbreak responses. Sanofi Pasteur is currently the only vaccine supplier to the UNICEF yellow fever vaccine stockpile.

Sanofi Pasteur is the largest provider of yellow fever vaccine worldwide with 200 million doses of vaccine provided to 150 countries over the past 20 years.

About yellow fever

Yellow fever is a viral disease that occurs in both rural and urban areas in Africa and South America. There is no treatment for yellow fever, only prevention by immunization. More than 200,000 people contract the disease and 30,000 people die from it each year. According to the WHO, over 30 countries in Africa (with an estimated population of 508 million) are at risk. In the Americas, yellow fever is endemic in nine South American countries and in several Caribbean islands.

About Sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2007, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: or

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by Sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

(1) Stamaril is a trademark of Institut Pasteur

SOURCE Sanofi Pasteur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
3. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
4. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
6. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
7. Pasteuria Bioscience Taps New CEO David N. Duncan
8. Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
9. UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key
10. Triage study challenges notions of emergency medical response to disaster
11. National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood
Post Your Comments:
(Date:10/9/2015)... 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) will ... conferences. th Annual BIO Investor Forum ... pm EDT). --> th Annual BIO ... PDT (2:00 pm EDT). --> Pulmatrix will ... Stock Conference on Thursday, October 15, 2015 at 8:30 am ...
(Date:10/8/2015)... , Oct. 8, 2015   Intrexon Corporation ... today announced the appointment of Joseph L. Vaillancourt ... succeeding Nir Nimrodi who continues in his ... direct Intrexon,s endeavors to generate sustainable, biologically based solutions ... , where he held a variety of key roles ...
(Date:10/8/2015)... N.C. and WAYNE, Pa. ... management and technology consulting firm, has announced the call ... Pennsylvania , majoring in a life ... over a two-year period. In addition, the selected Clarkston ... through mentoring with Clarkston Consulting and participation in Pennsylvania ...
(Date:10/8/2015)... -- The 2015 Nobel Prize in Chemistry has been ... Aziz Sancar , who earned his PhD in molecular ... 1977, is one of three scientists who received the Nobel Prize ... DNA on a molecular level.  --> Aziz Sancar , ... Dallas in 1977, is one of three ...
Breaking Biology Technology:
... LAFAYETTE, Ind. - Researchers are developing a technology that ... efficient by using a new manufacturing method that employs ... to overcome two major obstacles that hinder widespread adoption ... and increase the efficiency of converting sunlight into an ...
... announces that a new market ... Diabetic Retinopathy Therapeutics - ... ... and Market Forecasts to 2017 ...
... March 9, 2011 SPX Corporation (NYSE: ... acquisition of B.W. Murdoch Ltd, a leading engineering company ... The company is based in Auckland, New Zealand. Terms ... engineering team has decades of experience in the New ...
Cached Biology Technology:
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
(Date:9/30/2015)... 30, 2015  The U.S. Court of Appeals for ... ruling in favor of Crossmatch ™, affirming the ... company Suprema and its U.S. partner Mentalix violated Section ... provision that declares it unlawful to engage in "unfair ... of Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 ...
(Date:9/28/2015)... , Sept. 28, 2015 CLEAR, ... that its expedited traveler service is coming ... transforms travel, bringing a frictionless experience, serious ... "CLEAR offers our travelers an ... service," said Jim Smith , Executive ...
Breaking Biology News(10 mins):
... February 1, 2011. Fact: The sex of some species ... warm nests produce females, cooler nests, males. And although ... years, scientists now report that almost half of the turtle ... global warming may affect turtle reproduction. To bring attention to ...
... species present a serious environmental, economic and social problem ... biodiversity and ecosystem functions, such as nutrient cycling. Despite ... can dominate new habitats over native plants that technically ... tested assumption is that these plants are more abundant ...
... key to preventing deaths from measles. Despite the availability ... children worldwide, particularly in less-developed regions where vaccination coverage ... at the Johns Hopkins Bloomberg School of Public Health ... a dry powder, live-attenuated measles vaccine that can be ...
Cached Biology News:
... poor quality running into billions of ... under increasing pressure to reduce expensive ... microscopic distribution of ingredients is known ... as dissolution, stability, bio-availability and hardness. ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: